The new data – from the ARISE trial – found that Cobenfy wasn't statistically better than placebo at improving the widely ...

Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos ...

US pharma major Bristol Myers Squibb (NYSE: BMY) saw its shares fall 4% in after-hours trading on Tuesday, after it announced ...

In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

The therapy showed a two-point reduction in total PANSS score at week six against placebo with atypical antipsychotic.

Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...

According to analysts at BMO Capital Markets, non-obstructive hypertrophic cardiomyopathy would have meant a $1.3 billion ...

BMS said it will launch Cobenfy within the next few weeks and has set a price of $1,850 per month for the medicine, which is considerably more than the current, largely generic array of ...

Agitated patients are often prescribed antipsychotic medications and sedatives off-label, but this can pose a risk to the ...

Cobenfy, Bristol Myers Squibb’s once-promising schizophrenia drug, just failed its Phase III ARISE trial as an add-on therapy ...

PureTech’s biggest success to date is likely the development of schizophrenia med Cobenfy, which was known as KarXT until its FDA approval last fall, which followed BMS’ $14 billion Karuna ...